BlackRock
CCCC icon

BlackRock’s C4 Therapeutics CCCC Stock Holding History

BlackRock’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.9M Buy
7,896,718
+5,848,192
+285% +$20M ﹤0.01% 2871
2026
Q1 		$5.39M Buy
2,048,526
+78,712
+4% +$185K ﹤0.01% 3792
2025
Q4 		$3.76M Buy
1,969,814
+374,175
+23% +$886K ﹤0.01% 3931
2025
Q3 		$3.54M Sell
1,595,639
-232,975
-13% -$559K ﹤0.01% 3920
2025
Q2 		$2.61M Sell
1,828,614
-3,455,799
-65% -$5.03M ﹤0.01% 3993
2025
Q1 		$8.46M Sell
5,284,413
-274,438
-5% -$819K ﹤0.01% 3399
2024
Q4 		$20M Buy
5,558,851
+667,916
+14% +$3.32M ﹤0.01% 3056
2024
Q3 		$27.9M Buy
4,890,935
+339,425
+7% +$2.04M ﹤0.01% 2820
2024
Q2 		$21M Buy
4,551,510
+3,646,504
+403% +$21.7M ﹤0.01% 2962
2024
Q1 		$7.39M Sell
905,006
-898,427
-50% -$6.96M ﹤0.01% 3510
2023
Q4 		$10.2M Sell
1,803,433
-291,905
-14% -$666K ﹤0.01% 3389
2023
Q3 		$3.9M Buy
2,095,338
+8,775
+0.4% +$26.8K ﹤0.01% 3758
2023
Q2 		$5.74M Sell
2,086,563
-1,610,179
-44% -$5.18M ﹤0.01% 3668
2023
Q1 		$11.6M Buy
3,696,742
+75,609
+2% +$445K ﹤0.01% 3241
2022
Q4 		$21.4M Buy
3,621,133
+156,561
+5% +$1.3M ﹤0.01% 3000
2022
Q3 		$30.4M Buy
3,464,572
+66,974
+2% +$695K ﹤0.01% 2791
2022
Q2 		$25.6M Buy
3,397,598
+257,608
+8% +$2.27M ﹤0.01% 2947
2022
Q1 		$76.2M Sell
3,139,990
-265,992
-8% -$6.46M ﹤0.01% 2314
2021
Q4 		$110M Buy
3,405,982
+248,775
+8% +$9.84M ﹤0.01% 2163
2021
Q3 		$141M Buy
3,157,207
+524,783
+20% +$22.5M ﹤0.01% 1976
2021
Q2 		$99.6M Buy
2,632,424
+1,437,932
+120% +$51.5M ﹤0.01% 2254
2021
Q1 		$44.2M Buy
1,194,492
+54,901
+5% +$2.18M ﹤0.01% 2695
2020
Q4 		$37.8M Buy
+1,139,591
New +$33M ﹤0.01% 2647

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock's CCCC Position: Q2 2026 in Review

BlackRock increased its C4 Therapeutics (CCCC) stake by 285% in Q2 2026, buying an estimated $20M and bringing the position to 7,896,718 shares worth $36.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2871.

BlackRock first reported a position in CCCC in Q4 2020 and has held it in 23 quarters since. The position peaked at $141M in Q3 2021. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • BlackRock held 7,896,718 shares of C4 Therapeutics worth $36.9M as of Q2 2026.
  • BlackRock bought 5,848,192 C4 Therapeutics shares in Q2 2026, an estimated $20M.
  • C4 Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2871 holding.
  • BlackRock first reported a position in C4 Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • BlackRock's C4 Therapeutics position peaked at $141M in Q3 2021.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.